Загрузка...
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
BACKGROUND: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor...
Сохранить в:
| Опубликовано в: : | J Immunother Cancer |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5320726/ https://ncbi.nlm.nih.gov/pubmed/28239472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0220-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|